Oxford Immunotec Global PLC Ordinary Shares
OXFD
OXFD was delisted on the 5th of March, 2021.
79 hedge funds and large institutions have $385M invested in Oxford Immunotec Global PLC Ordinary Shares in 2017 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 27 increasing their positions, 33 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
13% more capital invested
Capital invested by funds: $340M → $385M (+$45.2M)
5% more funds holding
Funds holding: 75 → 79 (+4)
18% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 33
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$13.2M |
| 2 |
PA
Perceptive Advisors
New York
|
+$6.86M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$6.74M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$4.65M |
| 5 |
PC
Polar Capital
London,
United Kingdom
|
+$4.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
-$1.7M |
| 2 |
NLVP
New Leaf Venture Partners
New York
|
-$1.63M |
| 3 |
Renaissance Technologies
New York
|
-$1.24M |
| 4 |
SIM
Spark Investment Management
New York
|
-$1.06M |
| 5 |
Neuberger Berman Group
New York
|
-$439K |
OXFD Hedge Fund Activity: Q3 2017 in Review
79 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Oxford Immunotec Global PLC Ordinary Shares (OXFD) for Q3 2017, worth a combined $385M — up 13% from $340M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new OXFD positions and 4 closed out — a net gain of 4 holders — while 27 added to existing stakes and 33 trimmed.
The largest buyer was Invesco, adding an estimated $13.2M. The largest seller was Redmile Group, cutting an estimated $1.7M.
- 79 institutional investors held Oxford Immunotec Global PLC Ordinary Shares (OXFD) as of Q3 2017, up from 75 in Q2 2017.
- Funds reported $385M of Oxford Immunotec Global PLC Ordinary Shares stock for Q3 2017, up 13% quarter-over-quarter.
- 8 funds opened new Oxford Immunotec Global PLC Ordinary Shares positions in Q3 2017 and 4 closed out, a net change of +4 holders.
- The largest Oxford Immunotec Global PLC Ordinary Shares buyer in Q3 2017 was Invesco, an estimated $13.2M added.
- The largest Oxford Immunotec Global PLC Ordinary Shares seller in Q3 2017 was Redmile Group, an estimated $1.7M sold.
Based on aggregated 13F filings for Q3 2017.